Investigating the role of cortisol and growth hormone in fatty liver development: fatty liver index in patients with pituitary adenomas

Pituitary

Volumn 19, Issue 5, 2016, Pages 461-471

  Auer, Matthias K ^a   Stalla, Günter K ^a   Stieg, Mareike R ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Adrenal insufficiency; Cortisol; Cushing s disease; Fatty liver; Growth hormone

Indexed keywords

GLUCOSE; GLUTAMATE SYNTHASE; GROWTH HORMONE; HEMOGLOBIN A1C; HYDROCORTISONE; TRIACYLGLYCEROL;

ADRENAL INSUFFICIENCY; ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR MORTALITY; CASE CONTROL STUDY; CONTROLLED STUDY; CUSHING DISEASE; DISEASE ASSOCIATION; FATTY LIVER; FEMALE; GLUCOSE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; HUMAN; HYPOPHYSIS ADENOMA; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK FACTOR; SUBSTITUTION THERAPY; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; ADENOMA; AGED; BLOOD; CARDIOVASCULAR DISEASE; COMPLICATION; DEFICIENCY; HYPOPHYSIS TUMOR; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; SEVERITY OF ILLNESS INDEX;

ADENOMA; ADRENAL INSUFFICIENCY; ADULT; AGED; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; FEMALE; GROWTH HORMONE; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PITUITARY ACTH HYPERSECRETION; PITUITARY NEOPLASMS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84969754428     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-016-0726-1     Document Type: Article

References (55)

1. Clark JM (2006) The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 40:5–10
2. Vernon G, Baranova A, Younossi Z (2011) Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34:274–285
3. Targher G, Arcaro G (2007) Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 191:235–240
4. Clayton R, Raskauskiene D, Reulen R, Jones P (2010) Mortality and morbidity in Cushing’s disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab 96:632–642
5. Bülow B, Hagmar L, Mikoczy Z, Nordström CH, Erfurth EM (1997) Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol (Oxf) 46:75–81
6. Zueger T, Kirchner P, Herren C, Fischli S, Zwahlen M, Christ E, Stettler C (2012) Glucocorticoid replacement and mortality in patients with nonfunctioning pituitary adenoma. J Clin Endocrinol Metab 97:E1938–E1942
7. Dekkers O, Biermasz N, Pereira A, Roelfsema F, Van Aken M, Voormolen J, Romijn J (2007) Mortality in patients treated for Cushing’s disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 92:976–981
8. Feldt-Rasmussen U, Abs R, Bengtsson B-A, Bennmarker H, Bramnert M, Hernberg-Stahl E, Monson JP, Westberg B, Wilton P, Wuster C (2002) Growth hormone deficiency and replacement in hypopituitary patients previously treated for acromegaly or Cushing’s disease. Eur J Endocrinol 146:67–74
9. Johannsson G, Sunnerhagen KS, Svensson J (2004) Baseline characteristics and the effects of two years of growth hormone replacement therapy in adults with growth hormone deficiency previously treated for Cushing’s disease. Clin Endocrinol (Oxf) 60:550–559
10. Wagenmakers M, Roerink S, Gil L, Plantinga T, Smit J, Netea-Maier R, Hermus A (2015) Persistent centripetal fat distribution and metabolic abnormalities in patients in long-term remission of Cushing’s syndrome. Clin Endocrinol (Oxf) 82:180–187
11. Colao A, Pivonello R, Spiezia S, Faggiano A, Ferone D, Filippella M, Marzullo P, Cerbone G, Siciliani M, Lombardi G (1999) Persistence of increased cardiovascular risk in patients with Cushing’s disease after five years of successful cure. J Clin Endocrinol Metab 84:2664–2672
12. Rockall A, Sohaib S, Evans D, Kaltsas G, Isidori A, Monson J, Besser G, Grossman A, Reznek R (2003) Hepatic steatosis in Cushing’s syndrome: a radiological assessment using computed tomography. Eur J Endocrinol 149:543–548
13. Gardner CJ, Irwin AJ, Daousi C, McFarlane IA, Joseph F, Bell JD, Thomas EL, Adams VL, Kemp GJ, Cuthbertson DJ (2012) Hepatic steatosis, GH deficiency and the effects of GH replacement: a Liverpool magnetic resonance spectroscopy study. Eur J Endocrinol 166:993–1002
14. Nishizawa H, Iguchi G, Murawaki A, Fukuoka H, Hayashi Y, Kaji H, Yamamoto M, Suda K, Takahashi M, Seo Y (2012) Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement therapy. Eur J Endocrinol 167:67–74
15. Ichikawa T, Nakao K, Hamasaki K, Furukawa R, Tsuruta S, Ueda Y, Taura N, Shibata H, Fujimoto M, Toriyama K (2007) Role of growth hormone, insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in development of non-alcoholic fatty liver disease. Hepatol Int 1:287–294
16. Candia R, Riquelme A, Baudrand R, Carvajal CA, Morales M, Solís N, Pizarro M, Escalona A, Carrasco G, Boza C (2012) Overexpression of 11β-hydroxysteroid dehydrogenase type 1 in visceral adipose tissue and portal hypercortisolism in non-alcoholic fatty liver disease. Liver Int 32:392–399
17. Takahashi Y (2012) Essential roles of growth hormone (GH) and insulin-like growth factor-I (IGF-I) in the liver [Review]. Endocr J 59:955–962
18. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C (2006) The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC gastroenterology 6:33
19. Cuthbertson DJ, Weickert MO, Lythgoe D, Sprung VS, Dobson R, Shoajee-Moradie F, Umpleby M, Pfeiffer AF, Thomas EL, Bell JD (2014) External validation of the fatty liver index and lipid accumulation product indices, using 1H-magnetic resonance spectroscopy, to identify hepatic steatosis in healthy controls and obese, insulin-resistant individuals. Eur J Endocrinol 171:561–569
20. Otgonsuren M, Estep MJ, Hossain N, Younossi E, Frost S, Henry L, Hunt S, Fang Y, Goodman Z, Younossi ZM (2014) A single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). J Gastroenterol Hepatol 29:2006–2013
21. Calori G, Lattuada G, Ragogna F, Garancini MP, Crosignani P, Villa M, Bosi E, Ruotolo G, Piemonti L, Perseghin G (2011) Fatty liver index and mortality: the cremona study in the 15th year of follow-up. Hepatology 54:145–152
22. Aimaretti G, Corneli G, Razzore P, Bellone S, Baffoni C, Arvat E, Camanni F, Ghigo E (1998) Comparison between Insulin-Induced Hypoglycemia and Growth Hormone (GH)-Releasing Hormone + Arginine as Provocative Tests for the Diagnosis of GH Deficiency in Adults 1. J Clin Endocrinol Metab 83:1615–1618
23. Abdu T, Elhadd T, Neary R, Clayton R (1999) Comparison of the low dose short synacthen test (1 μg), the conventional dose short synacthen test (250 μg), and the insulin tolerance test for assessment of the hypothalamo-pituitary-adrenal axis in patients with pituitary disease. J Clin Endocrinol Metab 84:838–843
24. Gastaldelli A, Kozakova M, Højlund K, Flyvbjerg A, Favuzzi A, Mitrakou A, Balkau B (2009) Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 49:1537–1544
25. Mayo-Smith W, Hayes C, Biller B, Klibanski A, Rosenthal H, Rosenthal D (1989) Body fat distribution measured with CT: correlations in healthy subjects, patients with anorexia nervosa, and patients with Cushing syndrome. Radiology 170:515–518
26. Mendoza-Figueroa T, Hernandez A, Lopez MDL, Kuri-Harcuch W (1988) Intracytoplasmic triglyceride accumulation produced by dexamethasone in adult rat hepatocytes cultivated on 3T3 cells. Toxicology 52:273–286
27. Dourakis S, Sevastianos V, Kaliopi P (2002) Acute severe steatohepatitis related to prednisolone therapy. Am J Gastroenterol 97:1074–1075
28. Targher G, Bertolini L, Rodella S, Zoppini G, Zenari L, Falezza G (2006) Associations between liver histology and cortisol secretion in subjects with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) 64:337–341
29. Vegiopoulos A, Herzig S (2007) Glucocorticoids, metabolism and metabolic diseases. Mol Cell Endocrinol 275:43–61
30. Den Boer M, Voshol P, Kuipers F, Havekes L, Romijn J (2004) Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models. Arterioscler Thromb Vasc Biol 24:644–649
31. Letteron P, Brahimi-Bourouina N, Robin M, Moreau A, Feldmann G, Pessayre D (1997) Glucocorticoids inhibit mitochondrial matrix acyl-CoA dehydrogenases and fatty acid beta-oxidation. Am J Physiol Gastrointest Liver Physiol 272:1141–1150
32. Lemke U, Krones-Herzig A, Diaz MB, Narvekar P, Ziegler A, Vegiopoulos A, Cato AC, Bohl S, Klingmüller U, Screaton RA (2008) The glucocorticoid receptor controls hepatic dyslipidemia through Hes1. Cell Metab 8:212–223
33. Basu R, Singh RJ, Basu A, Chittilapilly EG, Johnson MC, Toffolo G, Cobelli C, Rizza RA (2005) Obesity and type 2 diabetes do not alter splanchnic cortisol production in humans. J Clin Endocrinol Metab 90:3919–3926
34. Paterson JM, Morton NM, Fievet C, Kenyon CJ, Holmes MC, Staels B, Seckl JR, Mullins JJ (2004) Metabolic syndrome without obesity: hepatic overexpression of 11β-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci USA 101:7088–7093
35. Morgan SA, McCabe EL, Gathercole LL, Hassan-Smith ZK, Larner DP, Bujalska IJ, Stewart PM, Tomlinson JW, Lavery GG (2014) 11β-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess. Proc Natl Acad Sci USA 111:2482–2491
36. Wake DJ, Rask E, Livingstone DEW, Söderberg S, Olsson T, Walker BR (2003) Local and systemic impact of transcriptional up-regulation of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity. J Clin Endocrinol Metab 88:3983–3988
37. Walker BR, Connacher AA, Lindsay RM, Webb DJ, Edwards C (1995) Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. J Clin Endocrinol Metab 80:3155–3159
38. Andrews RC, Rooyackers O, Walker BR (2003) Effects of the 11β-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab 88:285–291
39. Livingstone DE, Walker BR (2003) Is 11β-hydroxysteroid dehydrogenase type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats. J Pharmacol Exp Ther 305:167–172
40. Rosenstock J, Banarer S, Fonseca VA, Inzucchi SE, Sun W, Yao W, Hollis G, Flores R, Levy R, Williams WV (2010) The 11-β-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care 33:1516–1522
41. Sherlock M, Reulen R, Alonso AA, Ayuk J, Clayton R, Sheppard M, Hawkins M, Bates A, Stewart P (2009) ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. J Clin Endocrinol Metab 94:4216–4223
42. Adams LA, Feldstein A, Lindor KD, Angulo P (2004) Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology 39:909–914
43. Quinkler M, Miodini Nilsen R, Zopf K, Ventz M, Øksnes M (2015) Modified-release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency. Eur J Endocrinol 172:619–626
44. Johannsson G, Nilsson AG, Bergthorsdottir R, Burman P, Dahlqvist P, Ekman B, Engström BE, Olsson T, Ragnarsson O, Ryberg M, Wahlberg J, Biller BMK, Monson JP, Stewart PM, Lennernäs H, Skrtic S (2011) Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J Clin Endocrinol Metab 97:473–481
45. Giordano R, Guaraldi F, Marinazzo E, Fumarola F, Rampino A, Berardelli R, Karamouzis I, Lucchiari M, Manetta T, Mengozzi G (2015) Improvement of anthropometric and metabolic parameters, and quality of life following treatment with dual-release hydrocortisone in patients with Addison’s disease. Endocrine 51:360–368
46. Björnsdottir S, Øksnes M, Isaksson M, Methlie P, Nilsen RM, Hustad S, Kämpe O, Hulting AL, Husebye ES, Løvås K (2015) Circadian hormone profiles and insulin sensitivity in patients with Addison’s disease: a comparison of continuous subcutaneous hydrocortisone infusion with conventional glucocorticoid replacement therapy. Clin Endocrinol (Oxf) 83:28–35
47. Motamed N, Sohrabi M, Ajdarkosh H, Hemmasi G, Maadi M, Sayeedian FS, Pirzad R, Abedi K, Aghapour S, Fallahnezhad M, Zamani F (2016) Fatty liver index vs waist circumference for predicting non-alcoholic fatty liver disease. World J Gastroenterol 22:3023–3030
48. Yang B-L, Wu W-C, Fang K-C, Wang Y-C, Huo T-I, Huang Y-H, Yang H-I, Su C-W, Lin H-C, Lee F-Y (2015) External validation of fatty liver index for identifying ultrasonographic fatty liver in a large-scale cross-sectional study in Taiwan. PLoS ONE 10:e0120443
49. Sanyal AJ (2002) AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 123:1705–1725
50. Bohte AE, Werven JR, Bipat S, Stoker J (2010) The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. Eur Radiol 21:87–97
51. Mishra P, Younossi ZM (2007) Abdominal ultrasound for diagnosis of nonalcoholic fatty liver disease (NAFLD). Am J Gastroenterol 102:2716–2717
52. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55:2005–2023
53. Kozakova M, Palombo C, Paterni Eng M, Dekker J, Flyvbjerg A, Mitrakou A, Gastaldelli A, Ferrannini E (2012) Fatty liver index, gamma-glutamyltransferase, and early carotid plaques. Hepatology 55:1406–1415
54. Käräjämäki AJ, Pätsi O-P, Savolainen M, Kesäniemi YA, Huikuri H, Ukkola O (2015) Non-alcoholic fatty liver disease as a predictor of atrial fibrillation in middle-aged population (OPERA Study). PLoS ONE 10:e0142937
55. Bozkurt L, Göbl CS, Tura A, Chmelik M, Prikoszovich T, Kosi L, Wagner O, Roden M, Pacini G, Gastaldelli A (2012) Fatty liver index predicts further metabolic deteriorations in women with previous gestational diabetes. PLoS ONE 7:e32710